Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Liabilities and Shareholders Equity: 2022-2025

Historic Liabilities and Shareholders Equity for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Sep 2025 value amounting to $104.8 million.

  • Orchestra BioMed Holdings' Liabilities and Shareholders Equity rose 39.15% to $104.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $282.9 million, marking a year-over-year decrease of 13.11%. This contributed to the annual value of $76.2 million for FY2024, which is 20.00% down from last year.
  • According to the latest figures from Q3 2025, Orchestra BioMed Holdings' Liabilities and Shareholders Equity is $104.8 million, which was up 144.73% from $42.8 million recorded in Q2 2025.
  • In the past 5 years, Orchestra BioMed Holdings' Liabilities and Shareholders Equity registered a high of $161.6 million during Q2 2022, and its lowest value of $42.8 million during Q2 2025.
  • Over the past 3 years, Orchestra BioMed Holdings' median Liabilities and Shareholders Equity value was $82.6 million (recorded in 2024), while the average stood at $89.7 million.
  • As far as peak fluctuations go, Orchestra BioMed Holdings' Liabilities and Shareholders Equity surged by 69.50% in 2023, and later plummeted by 42.50% in 2024.
  • Over the past 4 years, Orchestra BioMed Holdings' Liabilities and Shareholders Equity (Quarterly) stood at $95.6 million in 2022, then dropped by 0.38% to $95.2 million in 2023, then declined by 20.00% to $76.2 million in 2024, then soared by 39.15% to $104.8 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $104.8 million for Q3 2025, versus $42.8 million for Q2 2025 and $59.1 million for Q1 2025.